Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
Immutep announced positive Phase II trial results for eftilagimod alfa (efti) combined with pembrolizumab and radiotherapy in soft tissue sarcoma patients, showing 81.1% 12-month disease-free survival. Patients with higher tumor-infiltrating lymphocyte levels (>310 cells/mm²) achieved 95.0% DFS, while those with greater treatment-related hyalinisation and fibrosis (>52%) reached 93.8% DFS. The company plans to advance efti into a registration-directed trial targeting initiation in H2 2027.


